Readiness for Insulin Pump Use in Pediatric Type I Diabetes:  A Quality Improvement Project by Marin, Valeria
University of the Incarnate Word 
The Athenaeum 
Doctor of Nursing Practice 
12-2020 
Readiness for Insulin Pump Use in Pediatric Type I Diabetes: A 
Quality Improvement Project 
Valeria Marin 
University of the Incarnate Word, valmari019@gmail.com 
Follow this and additional works at: https://athenaeum.uiw.edu/uiw_dnp 
 Part of the Pediatric Nursing Commons 
Recommended Citation 
Marin, Valeria, "Readiness for Insulin Pump Use in Pediatric Type I Diabetes: A Quality Improvement 
Project" (2020). Doctor of Nursing Practice. 82. 
https://athenaeum.uiw.edu/uiw_dnp/82 
This Doctoral Project is brought to you for free and open access by The Athenaeum. It has been accepted for 
inclusion in Doctor of Nursing Practice by an authorized administrator of The Athenaeum. For more information, 
please contact athenaeum@uiwtx.edu. 





READINESS FOR INSULIN PUMP USE IN PEDIATRIC TYPE I DIABETES: 









DNP PROJECT ADVISOR 
 
Danielle Gunter PhD, RN, CPN 















Presented to the Faculty of the University of the Incarnate Word 
in partial fulfillment of the requirements 
for the degree of 
 
 
DOCTOR OF NURSING PRACTICE  
 












As this journey ends, I would like to thank those who have uplifted me and helped me 
push through across the finish line. I want to thank Dr. Danielle Gunter for being an amazing 
guide to my project. I am so grateful to have shared a second academic journey with her as my 
professor at UIW and that she was always a call or text away to answer my questions and settle 
my worries. Second, I would like to thank my mentor, Dr. Rayas, and Ruby Favela-Prezas, NP 
for your loyalty and expertise to the project that allowed me to accomplish my project with a 
plan B. I am privileged to have been part of the diabetes care team and to have both of you as 
mentors in my career.  
To my husband, Francisco Alvarez, thank you for your patience, for never failing to 
make me laugh through the stress, and your daily reminders that I could do it. Gracias amor! To 
my partner in crime on our second nursing school journey, Renad Saadat, we did it! Lastly, I 
would also like to thank my amazing parents, Alberto and Magaly Marin, gracias por todo su 















TABLE OF CONTENTS 
LIST OF TABLES ...................................................................................................................... 6 
 
LIST OF FIGURES .................................................................................................................... 7 
 
ABSTRACT ............................................................................................................................... 8 
 
INTRODUCTION ...................................................................................................................... 9 
 
STATEMENT OF THE PROBLEM ......................................................................................... 11 
 
Background and Significance ........................................................................................ 11 
 
ORGANIZATIONAL ASSESSMENT...................................................................................... 15 
 
Organization’s Readiness for Change ............................................................................ 18 
 
PROJECT IDENTIFICATION.................................................................................................. 20 
 
Project Outcomes .......................................................................................................... 20 
 
Anticipating Outcome Measures .................................................................................... 21 
 
SUMMARY AND STRENGTH OF THE EVIDENCE ............................................................. 21 
 
Guideline Recommendations ......................................................................................... 21 
 
Benefits of CSII ............................................................................................................. 22 
 
Provider Roles in Management ...................................................................................... 24 
 
Culture, Health Disparities and Access .......................................................................... 25 
 
Complications from Misuse of Pumps ........................................................................... 26 
 
Process of Initiation ....................................................................................................... 27 
  





Table of Contents—Continued 
 
METHODS ............................................................................................................................... 28 
 
Project Intervention ....................................................................................................... 28 
 
Setting/Population ......................................................................................................... 32 
 
Organizational Barriers .................................................................................................. 32 
 
Organizational Facilitators ............................................................................................. 33 
 
Ethical Considerations ................................................................................................... 34 
 
EVALUATION PLAN ............................................................................................................. 35 
 
RESULTS ................................................................................................................................. 36 
 
Demographic Data ......................................................................................................... 36 
 
Outcome 1 ..................................................................................................................... 37 
 
Outcome 2 ..................................................................................................................... 38 
 
Outcome 3 ..................................................................................................................... 38 
 
Outcome 4 ..................................................................................................................... 39 
 
DISCUSSION ........................................................................................................................... 40 
 
Relation to Other Evidence ............................................................................................ 42 
 
Limitations .................................................................................................................... 42 
 
Recommendations ......................................................................................................... 44 
 
Implications for Practice ................................................................................................ 45 
 
REFERENCES ......................................................................................................................... 47 
 
APPENDIX A: Action Plan Table ............................................................................................. 53 
 
APPENDIX B: English and Spanish Patient Education Sheet .................................................... 61 





Table of Contents—Continued 
 
APPENDIX C: CDE Education Checklist for Pump Therapy .................................................... 63 
 
APPENDIX D: Diabetes Pump Care Assessment ...................................................................... 64 
 
APPENDIX E: Insulin Pump Vocabulary Review in English and Spanish................................. 68 
 
APPENDIX F: Letter of Support from Clinical Site Mentor ...................................................... 72 
 
  





LIST OF TABLES 
 
Table  Page 
 
1. Demographic Characteristics of Clinic’s Type 1 Diabetic Population............................. 17 
 















1. Diabetes Pump Care Assessment Scores ........................................................................ 39 
 
















INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES        8 
 
Abstract 
Background. Insulin pumps are essential in the management of type 1 diabetic pediatric patients 
because of their versatility in meeting the developmental needs of childhood and adolescence. 
Summary of the Evidence. There is lack of evidence for standardized pump initiation program in 
pediatric patients (ADA, 2019). Moreover, adverse events from insulin pump misuse, such as 
diabetic ketoacidosis, arise from lack of anticipatory guidance of pump management and 
troubleshooting (Evert et al., 2016; Grunberger et al., 2014, Wheeler et al, 2014). Project 
Purpose. The purpose of this quality improvement (QI) project was to reduce and prevent 
adverse outcomes of insulin pumps secondary to an inefficient initiation process, management, 
and patient/family understanding. Project Objectives. Objectives of this QI were: the 
implementation of a streamlined initiation process, assessment of patient knowledge through an 
additional education session including a pre-and post-test patient skills questionnaire, and to 
decrease adverse effects related to new insulin pump use. Results. 100% staff education was 
achieved, 67.5% of patients/families attended the new education session achieving an average 
score of 80% or higher on the skills questionnaire, and adverse effects related to new insulin 
pump usage decreased from a rate of 66% to 50% after implementation. Implications for 
Practice. Use of practice guidelines to implement a structured process for insulin pump initiation 
is a cost-effective strategy to promote patient ownership, improve patient knowledge, lower 
potential costs of clinic or hospital visits for adverse effects, and guide provider oversight in 
effective use of technology to improve patient outcomes and decrease barriers to care. 
Keywords: Insulin pumps, pediatric type 1 diabetes, CSII, insulin pump initiation 
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Readiness for Insulin Pump Use in Pediatric Type 1 Diabetes: 
A Quality Improvement Project  
 
 Type 1 diabetes mellitus is a chronic disease most common in children and adolescents, 
which is marked by an autoimmune process requiring the need for a lifetime of exogenous 
insulin dependence. According to the Centers for Disease Control and Prevention (CDC, 2017), 
during 2011-2012, there were 17,900 new diagnosed cases of type 1 diabetes in the United States 
in individuals younger than 20 years old. This chronic disease commonly affects non-Hispanic 
whites. However, Mayer-Davis et al. (2017) stated that between 2009-2012, Hispanic children 
and adolescents had an annual 4.2% higher incidence rate of type 1 diabetes than non-Hispanic 
whites. Currently, data about the incidence and prevalence of pediatric type 1 diabetic cases in 
the state of Texas, nor Bexar County are available. However, these national statistics exhibit 
implications for need of improved management of pediatric type 1 diabetes within its 
populations.  
The landmark Diabetes Control and Complications Trial highlighted the importance of 
intensive insulin treatment to prevent the progression of both macrovascular and microvascular 
comorbidities (Diabetes Control and Complications Trial Research Group, 1993). As a result of 
this clinical trial, the American Diabetes Association’s (ADA, 2018) clinical guidelines 
recommend tight metabolic control through strict insulin administration partnered with 
adherence to daily blood glucose monitoring, a carbohydrate-controlled diet, and active lifestyle 
to guide optimal health outcomes. It is imperative for pediatric type 1 diabetic patients to 
maintain therapeutic management since childhood is a crucial period for brain development and 
continuous maturation of brain functions (ADA, 2018). Therefore, this population has an 
increased risk for neurocognitive complications from diabetic ketoacidosis (DKA), such as 
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cerebral edema, hypoglycemia, seizures, and altered mental status (Cameron et al., 2014). 
Moreover, diabetic children just like diabetic adults are at risk of macrovascular comorbidities 
such as hypertension and atherosclerotic disease, as well as, microvascular complications, such 
as peripheral neuropathy and retinopathy (ADA, 2018).  
Although insulin pumps have existed for over 30 years, due to advancements in emerging 
health technologies in the past two decades, continuous subcutaneous insulin pumps (CSII) have 
become essential in type 1 diabetic care for pediatric patients because of their versatility in 
meeting the unique needs of children and adolescents. A significant barrier to achieving 
metabolic control within this population is disease burden due to changes in growth and 
development that influence insulin sensitivity, changes in parent and child roles, and need for 
external psychosocial support (ADA, 2018). Therefore, providers must meet the challenge of 
creating individualized treatment regimens that meet standards of care to achieve glycemic 
control, prevent complications of the disease, and are conducive to a healthy childhood 
(Woerner, 2014).  
Ehrmann et al. (2018) stated that in contrast to multiple daily injections (MDI), CSII 
therapy can replicate the body’s physiologic function of insulin secretion through advanced 
insulin infusion settings allowing for basal and bolus rates and advanced technology that provide 
real-time data of the body’s insulin needs. CSII therapy is a tool that individualizes care for 
children and adolescents due to their increased energy and metabolic needs and allows for 
normality of care in the management of type 1 diabetes. Insulin pump therapy also lessens the 
burden of multiple daily needle sticks, a significant stressor of diabetes management in pediatric 
populations. CSII pump therapy requires a one-time injection every 2 to 3 days compared to 
multiple daily injections for insulin administration (Sherr et al., 2018; Woerner, 2014). However, 
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the success of adhering to insulin pump therapy in children and adolescents is dependent on the 
patient and family readiness to transition from MDI to CSII. Preparation for insulin pump use is 
determined through education, health literacy, access to care, and continuation of a therapeutic 
relationship with the healthcare team.  
Statement of the Problem 
The selected DNP project site was an urban pediatric endocrinology clinic located in 
south Texas. The problem was the lack of a standardized protocol for the providers’ initial 
readiness assessment and for the continuous evaluation of barriers to successful insulin pump 
adherence with children and adolescents. It is essential for providers to assess the pediatric 
patient’s motivation to adhere to the use of this technology and anticipate needs, such as health 
literacy, cost/medical insurance, and social support that can create obstacles in the transition 
process from multiple daily insulin injections to use of a wearable continuous insulin infusion 
pump (Grunberger et al., 2014). Furthermore, providers must be capable of managing these 
devices to provide satisfactory patient education that will improve patient outcomes related to 
their diabetes, such as decreasing the hemoglobin A1C level, preventing hypoglycemic events, 
and decreasing symptoms of hyperglycemia. Also, clinical providers must reinforce the training 
by being part of a diabetic care team which provides holistic clinical support during the transition 
to CSII pump therapy (Grunberger et al., 2014; Shulman et al., 2016).  
Background and Significance 
The cornerstone of diabetic care and management is aimed at preventing the progression 
of disease morbidity and comorbidity. Complications of mismanaged type 1 diabetes in children 
can have debilitating pathophysiological complications that affect the neurologic, cardiovascular, 
and urinary systems. The body’s central nervous system uses glucose to carry out essential 
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cognitive and sensorimotor functions which can be easily disrupted by frequent abrupt 
imbalances of normoglycemia. Hypoglycemia can impede cognition, causing altered mental 
status, hypoglycemia unawareness, and fatal seizures (Bratina et al., 2018; Cameron et al., 2014). 
On the other hand, hyperglycemia can also cause altered cognition, diminish body energy, and 
result in a medical emergency such as DKA (Bratina et al., 2018; Cameron et al., 2014). These 
glycemic extremes can also stress peripheral nerves causing progressive sensorimotor loss 
exhibited by retinopathy and peripheral neuropathy (Donaghue et al., 2018). In the 
cardiovascular system, macrovascular complications are related to the early development of 
hypertension and hyperlipidemia increasing the risk for cardiovascular disease especially for 
adolescents with type 1 diabetes (Donaghue et al., 2018). Moreover, the lack of glycemic control 
also affects the urinary system through alterations of renal function and morphology that can 
result in progressive loss of kidney function (Donaghue et al., 2018). 
 With advanced diabetic technology, routine diabetic care is not enough to prevent 
complications of type 1 diabetes, and additional competence, knowledge, and responsibility are 
required. Currently, consensus among clinical guidelines for the use of diabetic technology 
recommend criteria for insulin pump use in pediatric patients to include the ability to self-
monitor blood glucose at least four or more times a day, lack hypoglycemic control despite 
adherence to MDI therapy, fluctuating glucose levels from day to day, and recurrent episodes of 
hypoglycemia (ADA, 2019; Grunberger et al., 2014; Sherr et al., 2018). However, without 
adequate education, resources, and efficient communication between patients/ families and the 
multidisciplinary healthcare team during the initiation of CSII therapy, informed clinical 
decisions cannot be made even if guideline criteria are met. Providers must increase their 
awareness of modifiable and nonmodifiable barriers to insulin pump initiation. Modifiable 
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barriers are health literacy, problem-solving in the event of a pump malfunction/accidental 
discontinuation, and overall family and social support of using an insulin pump.  
Pulgaron et al. (2014) identified that the patient and family’s level of health literacy, 
especially numeracy skills, is a significant predictor of successful pediatric diabetes management 
and glycemic control. Pulgaron suggested the use of the Diabetes Numeracy Test, a valid 
screening tool that tests numeracy skills used in standard diabetic education such as insulin-to-
carbohydrate ratio and interpretation of blood glucose levels to insulin coverage, as part of 
routine diabetes care. Evaluating the degree of competence in these necessary skills prior to 
insulin pump initiation is crucial because the patient and his or her parents will be required to 
learn new terminology that involves knowing how to adjust insulin pump settings for basal and 
bolus rates which are also dependent on blood sugar monitoring and an insulin-to-carbohydrate 
ratio (Hirose et al., 2012). The benefits of advanced pump settings are that they help decrease the 
risk of hypoglycemic events since they tailor insulin administration to meet a child’s day-to-day 
activities/ energy needs and insulin sensitivity trends (Sherr et al., 2018).  
Patient and parental knowledge of advanced insulin pump settings and understanding of 
pump alarms influence their ability to troubleshoot their pump in case of a pump malfunction. 
Results of a prospective study by Wheeler et al., (2014) exhibited increased adverse effects, such 
as diabetic ketoacidosis or blocked insulin delivery, in children younger than 10 years old. 
Therefore, providers must educate parents about realistic, anticipatory challenges in 
acknowledging pump malfunction due to their child’s age and development. Problems that 
present in early childhood are the growth of autonomy, increased susceptibility to illness, the 
variability of diet and physical activity, and lack of ability to verbalize or identify signs and 
symptoms of both hypoglycemia and hyperglycemia (Markowitz et al., 2015). In contrast, 
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though adolescents may have the understanding and developmental skills to manage the 
technology of insulin pumps, too much autonomy in their diabetes care can also increase the risk 
of adverse effects through a lack of adherence to diabetes care management (Markowitz et al., 
2015). In anticipation of these challenges, the American Academy of Clinical Endocrinologists/ 
American College of Endocrinology (AACE/ACE) guidelines recommend that healthcare 
providers distribute a diabetes action plan prior to pump initiation to patient and families to help 
guide them in how to assess their pump, reinstate a new pump, or if needed, return to insulin 
injection therapy for a short time frame (Grunberger et al., 2014).   
Lastly, due to the increased skills needed to adhere to insulin pumps, overall 
sociodemographic support outside the clinical setting can also present nonmodifiable barriers to 
proper insulin pump initiation. Since children spend most of their day-to-day lives in school or 
extracurricular activities, the provider and diabetes healthcare team need to assure 
communication between a school nurse or teacher and partner with community resources, like a 
support group, in order to enhance the child and the family’s transition to a pump and promote 
continuity of regimen (Corathers et al., 2015). Moreover, the most significant barrier to obtaining 
an insulin pump is medical insurance coverage, especially for minority pediatric patients, African 
Americans, and Hispanics, and those with public health insurance or no health insurance 
(O’Connor et al., 2018). In Texas, Sheikh et al., (2018) assert that despite increased coverage of 
insulin pumps from Medicaid and CHIP, disparities in the use of insulin pumps in minority 
groups and those with lower English proficiency persist. Additionally, evidence in the literature 
suggests in the United States, higher HbA1c and lack of glycemic control are seen in minority 
children with type I diabetes as well as those who have public insurance (Sheikh et al., 2018; 
Watson et al., 2017). Awareness of these disparities can also prompt a provider to acknowledge 
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any personal biases in their recommendations for insulin pumps and to offer comprehensive 
learning materials that are culturally sensitive, easy to read, or are available in different 
languages so that equity of insulin pump benefits is provided (O’Connor et al., 2018; Sheikh et 
al., 2018; Shulman et al., 2016).  
Organizational Assessment  
A key component to improving clinical practice is through an assessment of the day-to-
day functions and interactions between the clinical setting, the healthcare team, and its patients. 
The selected site for this quality improvement project was a pediatric endocrinology outpatient 
practice in south Texas. The clinic was located inside a comprehensive diabetes center from a 
recognized healthcare system that is also an academic learning facility. The clinic not only seeks 
to offer quality care to children with endocrinologic conditions in the urban area, but also those 
from surrounding south Texas communities extending to the Rio Grande Valley. The top three 
diagnoses treated in the clinic are both type 1 and type 2 diabetes mellitus, thyroid conditions, 
and disorders of growth & development. Each provider sees between 16 to 18 patients a day, 
with six to eight of them being diabetic patients.  
The multidisciplinary diabetic care team consisted of five physicians, one family nurse 
practitioner (FNP), three certified diabetes educators (two who are certified dieticians, and one 
who is a registered nurse), and a licensed clinical social worker. Clinic hours ran Monday 
through Friday from 7:30 a.m. to 4:30 p.m. The providers had set clinic days and a rotating on-
call schedule during the week and weekends for patients’ admissions at two different hospitals in 
the city. A minimum of two providers saw patients within a given day. Since it was a learning 
facility, medical students, residents, and fellows also saw patients under the supervision of the 
designated provider. The NP worked part-time and was in the clinic three times a week. At least 
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one diabetes educator (CDE) was present every day, and they also had an on-call schedule to see 
hospitalized patients due to a new diagnosis of diabetes. The licensed social worker was also 
present in the clinic Monday through Friday but shared some responsibility in care coordination 
for an additional pediatric subspecialty clinic. The supportive staff that were also present during 
clinic hours were two front desk staff, three medical assistants, three LVNs, a nurse educator, 
and the clinic supervisor who was a RN.  
Since this clinic was part of a non-profit health system, most of the patient population had 
Medicaid (Superior Star)/CHIP or were uninsured. However, as this was a pediatric subspecialty 
clinic that served more than just the one urban community, the clinic also had a significant 
population of patients with private health insurance. This clinic had a comprehensive, 
interprofessional approach to care, which allowed them to have adequate resources to help 
pediatric diabetic patients and their families afford high-quality care even with insurance 
barriers.  
The sociodemographic characteristics of the clinic’s type 1 diabetic patients were 
predominately 82.1 % white and 19.4% of the total population spoke Spanish (see Table 1). 
Three of the providers, the NP, and one CDE, spoke fluent Spanish, and one MA was also a 
certified Spanish interpreter. Patients’ ages range from a couple of months old to 17 years of age. 
The healthcare team follows ADA 2019 standards of care through focusing on health indicators 
such as glycemic control by checking HbA1c in clinic every 3 months, offering continuing 
diabetic education with a CDE at each visit, routinely communicating with patients and families 
through phone calls, and providing resources of support for diabetes management such as access 
to affordable medications and diabetic devices. 
 
 




Demographic Characteristics of Clinic’s Type 1 Diabetic Population 
 
Demographic No. (%) of Patients 
(n = 134) 
Gender 
    Male 






















Note. Data derived from clinic’s 2019 records.  
In 2019, there were estimated 134 type 1 diabetic pediatric patients seen at the clinic, and 
between 20-40 patients had started managing their disease with an insulin pump. While provider 
preference determined to whom he or she recommended insulin pump therapy, there was no 
standard protocol that they followed to initiate the insulin pump process or evaluate the patient 
and family’s readiness for change. In meeting with three of the MDs and the FNP, a consensus 
among their decision to start a patient on an insulin pump was determined by the patient’s ability 
to consistently check blood sugars more than twice a day, have been diagnosed for more than a 
year, be compliant with an adjunct care regimen such as carb counting, and have 
parental/guardian support.  
When a provider offered insulin pump therapy to a patient, the benefits of insulin pumps 
to daily insulin injections were discussed. Due to clinic visit time constraints, the provider then 
alerted the CDE to provide patient information brochures to the patient and family and they also 
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briefly discussed the different types of insulin pumps. The patient and family were given time to 
ask questions. Then, the CDE and provider encouraged the patient and family to look over the 
information provided, to do some online research of their own, and to consult their insurance to 
inquire what type of coverage they could obtain with the desired insulin pump. One barrier 
identified in this step was that the patient and family were not always told to call the clinic back 
when they had made a decision on a pump or that additional information was needed to order an 
insulin pump, such as blood sugar logs 3 months prior and demographical information. The 
CDEs verbalized that significant delays in the waiting period from when a pump is decided to the 
time of the patient and family receiving the pump occurred because parents didn’t understand the 
process of ordering a pump, or the importance of following through with their health insurance 
about cost and coverage. Additionally, the LVNs and MAs verbalized breakdowns in current 
communication between providers and CDEs regarding when to initiate the order for an insulin 
pump, and lack of available patient data such as blood sugar logs that they needed to follow up 
on, which also delayed the delivery of an insulin pump. On average, the waiting period for the 
approval and delivery of an insulin pump from insurance companies, both public and private, 
ranged from 1 to 4 months.  
Once an insulin pump was delivered to the patient’s home, the family was expected to 
notify both the insulin pump company representative and their clinic provider. The insulin pump 
representative provided an insulin pump start class that covers the mechanical aspects and 
settings about how to use the pump, and it was also the first time when the pump was placed on 
the child. For this class to occur, the provider needed to be notified to write for insulin delivery 
orders with the pump. This pump start class also took place in the clinic in an education room; 
however, it was not considered an in-clinic visit. Rather it was a courtesy, free-of charge 
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education session provided by the representative for the insulin pump company. After this 
session, the pump representative walked the patient family to the front desk for them to schedule 
a follow up appointment within 1 week with the CDE to obtain more insulin pump education. 
The provider may or may not see them on that visit, but providers stated that usually the patient 
was seen within 3 months. The providers verbalized their awareness of issues with patient’s lack 
of knowledge on how to use the device during the first months after insulin pump initiation, 
which resulted in the self-discontinuation of the device or incorrect use of the pump. The CDEs 
also verbalized issues with parents not understanding the importance of following up for pump 
initiation class after receiving their pump.  
Organization’s Readiness for Change       
 To assess the clinic’s readiness for a change process to take place, key stakeholders of the 
diabetic care team were interviewed to gain perspective on what are the needs for improving the 
insulin pump initiation process. Using the Practice Improvement Capacity Rating Scale, a 
physician leader, the nurse practitioner, a CDE, and an LVN were interviewed to assess the 
practice’s readiness for quality improvement to take place (Aligning Forces for Quality, 2014). 
By using a scoring system, this tool also evaluates how current resources in practice can facilitate 
change. Results from the interviews exhibited an average score of 200, which identifies the 
practice that has a limited capacity initiation of a QI process (Aligning Forces for Quality, 2014).  
The barriers identified during the interviews, are related to the lack of a QI officer or QI 
team in place at this clinic that incorporates both providers and clinical staff. Past QI projects 
were carried out by the provider team with little to no input of the clinic staff or have been QI 
projects carried out by the larger health system with little provider input. There was also lack of 
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communication between clinic staff and provider staff about change processes and initiatives due 
to the lack of regular all clinical staff meetings.  
A facilitator identified in these interviews was that both the clinical staff and the 
providers recognized a need for a change process regarding a streamlined initiation process for 
insulin pumps. The staff also recognized the need to have better team cohesiveness in quality 
improvement initiatives so that everyone who is involved in patient care or interaction has a 
voice. Overall, the staff showed support for improved communication strategies and were 
motivated to take part in quality improvement initiatives.  
Additionally, ten patients and their parents who had recently been recommended to start 
an insulin pump therapy or had recently initiated a pump were interviewed to explore their needs. 
The feedback provided by the patients and families revealed unawareness of insurance 
coverage/cost and confusion about what to do when the pump arrives. Therefore, the cumulative 
stakeholder interviews supported the need for an improved process of insulin pump therapy.  
Project Identification 
 The purpose of this DNP quality improvement project was to reduce and prevent adverse 
outcomes of insulin pumps secondary to an inefficient initiation process, management, and 
patient/family understanding by implementing a streamlined process, increasing assessment of 
patient management strategies, and improving patient education.  
Project Outcomes  
 There were four project outcomes for this project. The first outcome was to streamline 
the insulin pump initiation process and educate staff about the new process. The second outcome 
was to increase patient and family knowledge about insulin pumps before starting CSII therapy 
by incorporating an additional CDE visit before the insulin pump initiation. The third outcome 
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was to increase the number of patients that receive appropriate standard of care insulin pump 
management education. Lastly, the fourth outcome was to reduce the number of adverse events 
related to pump mismanagement leading to decreased control of diabetes.  
Anticipated Outcome Measures 
1. By February 12th of 2020, 100% of staff and providers will receive education about the 
new insulin pump approval process.  
2. By August 1st of 2020, 75% of patients that have requested insulin pump therapy will 
attend both CDE educations visits and receive appropriate pump management education.  
3. Patient-level of knowledge will show improvement from pre-pump start education to 
post-pump start secondary education, evidenced by achieving a score of 80% or higher on 
both the diabetes care assessment test and pump terminology test. Also, patients will have 
90% of the education checklist completed by post-insulin pump start visit.  
4. By July 2020, there will be a 30% decrease of insulin pump-related adverse events 
such as calls about pump malfunction or issues, and unexpected hospitalizations from the 
current rate of 66% related to an insulin pump issue.  
Summary and Strength of the Evidence 
Guideline Recommendations 
Evidence-based guidelines from the ADA, AACE/ACE, and ISPAD provided high-
quality evidence of the safety and efficacy of insulin pumps for child and adolescent type 1 
diabetic patients (ADA, 2018; Grunberger et al., 2014; Sherr et al., 2018). The ADA (2018) 
recommends that providers who initiate CSII therapy on pediatric patients must perform an 
initial comprehensive patient readiness assessment which includes:  
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• Assessment of individual patient and family knowledge and health literacy regarding 
CSII and diabetes management. 
• Selection of pump type (loop pump, closed loop, or CGM sensor augmented) and 
prescribing initial pump settings. 
• Insurance coverage of insulin pump and supplies.  
• Family education about potential pump complications and pump failure action plan to be 
prepared in an emergency, an episode of DKA, or a pump malfunction 
• Introduction and education of pump settings and terminology.   
The ISPAD guidelines assert that an assessment of these focus areas aids providers in 
exploring potential barriers to successful CSII therapy (Sherr et al., 2018). Nevertheless, the 
three guidelines do not mention the use of valid screening tools or decision aids that can be used 
to assess these potential barriers. Rather, the guidelines recognized the need for further research 
and implementation of successful tools, frameworks, or clinical processes of cost-effective 
insulin pump-focused diabetes education (ADA, 2018; Grunberger et al., 2014; Sherr et al., 
2018).  
Benefits of CSII  
There is limited evidence from systematic reviews and RCTs showcasing the success of 
CSII in pediatric type 1 diabetes management over multiple daily injections for significant 
improvement in HbA1c control over long-term periods. However, there is successful evidence of 
the benefits of CSII over MDI therapy in children and adolescents (Ly et al., 2013; Rosner & 
Roman-Urrestarazu, 2019; Yeh et al., 2012). Yeh et al. (2012) is a systematic review and 
metanalysis that found CSII therapy to reduce hypoglycemic rates in children due to the usage of 
certain pumps which incorporate a continuous glucose monitor device to correctly administer 
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insulin based on real-time blood sugars or are sensor augmented to stop infusing when the blood 
sugars are low preventing the administration of too much insulin. Ly et al. (2013) supported this 
finding in an RCT that compared a sensor augmented insulin suspension pump group to a regular 
pump group. Results of the study found a lower incidence of moderate to severe hypoglycemic 
events, from 175 to 35, in the sensor augmented pump group compared to the regular pump 
group, 28 to 16 (Ly et al., 2013). Hypoglycemia unawareness is a common symptom of pediatric 
type 1 diabetic patients under the age of 12. Therefore, advance insulin pumps settings and 
features are beneficial in preventing adverse effects.  
Versality of care that CSII therapy provides has also been studied in a recent systematic 
review focused on the association between health-related quality of life and pediatric type 1 
diabetes management (Rosner & Roman-Urrestarazu, 2019). Out of the fifteen studies reviewed, 
the researchers found improved pediatric quality of life scores and increased patient satisfaction 
with the use of CSII therapy than MDI therapy from baseline to post intervention follow up. Yeh 
et al., (2012) also stated increased patient satisfaction with diabetes management due to lack of 
multiple daily needle sticks and flexibility of adjusting insulin basal and bolus rates with 
activities that such as exercise or meal and snack times.  
Many of the limitations seen in these studies are related to small sample sizes of child 
participants. Recommendations offered by these systematic reviews and the RCT is the need for 
better studies, like RCTs, that account for larger sample sizes, increased diversity in selected 
participants, and studies with extended implementation periods to fully understand benefits and 
complications of CSII use in children and adolescents and their long-term effects of morbidity 
and mortality (Ly et al., 2013; Rosner & Roman-Urrestarazu, 2019; Yeh et al., 2012). 
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Provider Role in Management  
Provider role in management of CSII therapy is crucial since providers can influence how 
well a pediatric patient and his or her family adapt to new diabetes technology and how well a 
patient adheres to its proper use. Markowitz et al., (2015) highlighted the importance of the 
provider’s acknowledgment and understanding of the dynamic roles in diabetes management 
between children and parents since growth and development of an individual child can influence 
behaviors in care. An evidence-based strategy that providers can use with school age and 
adolescent patients who are initiated on a pump therapy is motivational interviewing, a 
communication style which reinforces a child’s personal motivational behaviors and tailors them 
to specific care goals such as lowering A1c, better eating habits, increasing self-sugar checks 
(Markowitz et al., 2015). Including the pediatric patient in the decision-making process of 
selecting a pump they will feel comfortable in wearing and allowing them to be an active 
participant in age-appropriate, shared responsibilities of diabetes care is another way that 
providers can support successful insulin pump adherence (Grunberger et al., 2014; Markowitz et 
al., 2015).  
Another vital part of the provider role is the frequency and continuity of patient follow up 
after insulin pump initiation to reassess how insulin pump therapy is benefiting an individual 
patient. By ADA and ISPAD standard of care, children with insulin pumps need to be seen in 
clinic every 3 months for routine care (ADA, 2018; Sherr et al., 2018). Moreover, Johnson et al. 
(2013) found that additional patient education hours at pump initiation by a diabetic care team 
and provider follow-ups phone calls in between routine clinic visits during the first months of 
using a pump resulted in a decreased rate of diabetic ketoacidosis in the insulin pump group that 
received education compared to standard diabetic care with MDI.  
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Culture, Health disparities and Access 
Cross-sectional studies found in the literature provided high-quality evidence of research 
about potential strategies to overcome barriers to successful adherence to CSII in pediatric type 1 
patients. Shulman et al., (2016) highlighted the importance of provider self-awareness of any 
personal biases for whom they recommend insulin pumps to ensure health equity, as decreased 
rates of insulin pump use are seen in minority children and families with public health insurance, 
and low socioeconomic backgrounds. For that reason, providers must also be aware of current 
insurance coverage for this type durable medical equipment since access to insulin pumps is also 
influenced by cost. Despite increased Medicaid and private insurance funding for insulin pumps 
in recent years, the cost of insulin pumps and supplies can range from $3,000 to $8,000 a year 
(Sherr et al., 2018). Since CSII is notably more expensive than MDI therapy, a structured 
education process for insulin pump initiation could be a cost-effective strategy to not only secure 
the therapy benefits but also lower potential costs of frequent clinic visits or hospital admissions 
due to therapy non-adherence. 
Moreover, Sheikh et al. (2018) also stated that there are evident disparities in the equity 
of insulin pump use in Spanish-speaking patients due to limited English proficiency and possible 
low socioeconomic backgrounds. Implications for practice from this study recommend that 
providers and clinics have comprehensive education materials in both Spanish and English or 
provide readily available translation services to improve access to diabetic care technology 
(Sheikh et al., 2018).  
For low English-proficient individuals, health literacy is another contributor to the lack of 
proper insulin pump use and access. Pulgaron et al. (2014) studied the relationship between the 
health literacy independent variables of parental numeracy skills, parental reading skills, and 
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parental perceived diabetes self-efficacy on type 1 diabetes glycemic control in a cross-sectional 
study. The results of the study found an inverse correlation between higher parental numeracy 
skills and lower HbA1c scores (r = −.52, p <.01) as well as higher parental self-efficacy and 
lower HbA1c scores (r = −.47, p <.01) (Pulgaron et al., 2014). This study added to the 
importance of providing the right education tools that reinforce of health literacy skills for 
parents of type 1 diabetic children and the need for recurrent evaluation of these skills with 
diabetic technology since its success relies heavily on parents having these skills to properly use 
the device for their child’s disease management. By improving the delivery of care and 
combating these barriers, providers can positively influence minority patients and low English 
proficiency individuals to increase compliance with disease management and decrease unplanned 
adverse events such as medication errors or emergency room visits.  
Complications from Misuse of Pumps 
 Both human and technological factors can impact how well a patient succeeds in safely 
using insulin pumps. Rosner and Roman-Urrestaruzau (2019), found that there was a higher 
incidence of DKA in CSII therapy than MDI therapy and could be a result of human factors such 
as pump malfunction, lack of knowledge of correct pump settings, and relaxed attitude to self-
management. Relaxed management is a significant factor in the case of a pediatric patient. A 
child or adolescent may discontinue their pump without their parent’s knowledge due to factors 
such as device discomfort or self-consciousness of body image in front of peers (Grunberger et 
al., 2014). Blood sugar levels can rise quickly, 1mg/dL for every minute of being off the insulin 
pump for more than 1 hour (Deiss et al., 2016). Additionally, when school age children and 
adolescents are given too much independence in their diabetic care, such as being the ones 
responsible for inputting their blood sugar data or carbohydrate counts into their pump, they can 
INSULIN PUMPS & PEDIATRIC TYPE 1 DIABETES        27 
 
incorrectly put in data in an effort to not get in trouble for eating a snack that increased their 
blood sugar, which will then prompt the pump to administer incorrect doses of insulin. These 
actions can lead to detrimental effects of incorrect pump usage. Moreover, Deiss et al. (2016) 
noted the importance of patient and parents in recognizing causes pump failure events. For 
example, an interruption of insulin flow should be suspected with any insulin pump-dependent 
patient that experiences unexplained glycemic variability, unexplained hyperglycemia, or 
frequent hypoglycemic/hyperglycemic episodes (Deiss et al. 2016). With the help of 
downloadable pump data, providers can also help recognize and evaluate these events prompting 
education reinforcement for safe use of the devices.  
Process of Initiation 
 There is lack of evidence evaluating a standard pump initiation program for pediatric type 
1 diabetic patients (ADA, 2018). However, a recent RCT by Ehrmann et al. (2018) showed 
promise of the efficacy of a structured program called Insulin Pump Treatment (INPUT) for type 
1 diabetic adolescent and adult insulin pump users. In this study the intervention arm attended 
the INPUT program which provided 12, biweekly, 90-minute group education sessions provided 
by a diabetes educator and the control group received no intervention. Participants of the study 
were between the ages of sixteen and seventy-five years of the sample population of n =266, n = 
125 participants were in the intervention group. Significant results of this RCT showed that 
INPUT group had an improved HbA1c scores (20.28% [23.1 mmol/mol]; P , 0.0001), had a 
lower incidence of severe hypoglycemic events requiring help from another person, increase 
self- reported use of pump advance settings, as well as decreased diabetes distress and depression 
symptoms compared to the control group (Ehrmann et al., 2018). The success of this RCT 
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highlights the need for studies that reflect the efficacy of structured insulin pump initiation and 
management education in pediatric patients.  
Methods 
 Project Intervention 
The focus of the project implementation was to deliver a more effective transition to 
insulin pump therapy process for patients and families. The details of this action plan are 
provided in Appendix A. Before the implementation of the new streamlined process for insulin 
pump initiation, the clinic staff and providers completed an education session given by the DNP 
student. This education session was given in person during the February monthly staff meeting 
and on an individual basis for those who were not able to attend. The DNP student provided a 
handout to the staff outlining the new streamlined process. This handout was also emailed to all 
clinic staff, and a printed copy was stored within the clinic protocol folder to be available for 
staff reference.  
Identification of Readiness for Insulin Pump Use 
The new process began with the initial routine clinic visit when the provider decided if a 
patient meets the guideline criteria for the initiation of an insulin pump. The provider introduced 
the patient to insulin pumps and discussed how they differentiated from insulin injections and 
their benefits to improve diabetes lifestyle and management. The CDEs distributed patient 
education brochures, already available in the clinic, about the different types of insulin pumps. 
Prior to implementation, this was all that occurred in the initial visit. However, in the 
organizational assessment, the clinic staff recognized the lack of consistent information given to 
patient families about the steps required before an insulin pump is ordered and delivered to the 
patient. For this reason, a patient education handout that outlined the steps for preparing for 
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insulin pump therapy, “Pathway to Insulin Pump Therapy”, was distributed to the patient and 
family. This patient education handout (Appendix B) was made by the DNP student and written 
at a 6th grade reading level in both English and Spanish. It was given at the end of the clinic visit 
with the patient’s discharge paperwork. Both the providers and CDEs were responsible for 
documenting, respectively, what was discussed, and the educational materials given to the 
patient during this initial visit. The provider SOAP note also stated that part of the care plan is 
for the patient to attend a pre-insulin pump education visit with the CDE. To encourage 
continuity of care, during discharge, the front desk staff was responsible for making an 
appointment for the pre-insulin pump education with CDE, which took place 3 to 4 weeks after 
the initial visit.  
Orders for Implementation 
The second implementation step was a follow-up phone call by the LVNs to the patient 
within 1 to 2 weeks of the original clinic visit when an insulin pump was discussed to inquire if 
the family had decided on which insulin pump they wanted to use. The LVNs oversaw the 
submission of diabetic device order forms to insurance companies; therefore, they also were 
responsible for documenting this communication in the patient’s electronic chart and 
messaging/communicating to the patient’s provider and CDEs about the family’s decision. With 
the old process prior to implementation, there was no consistent follow through with the patient’s 
family leading to miscommunication between the LVNs, the CDEs, and providers about the 
patient’s decision and the personal information needed. This resulted in increased wait times for 
insulin pump ordering. A facilitator for this step was that the clinic’s staff and providers use a 
secure messaging system and the institution’s email to communicate about patient matters and 
these messaging applications were used on a daily basis in the clinic by all staff. The LVN then 
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notified the CDE through secure messaging about the patient’s insulin pump choice. Once the 
CDE was notified, they were responsible for contacting the insulin company representatives to 
alert them that they had a new patient with their device which helped speed up both the insurance 
approval process and waiting period for insulin pump delivery to the patient.  
Patient Education for Pump Utilization 
In the past, the patient was not seen back in the clinic until the insulin pump was 
delivered. At that time, an insulin pump start class was provided by the respective insulin pump 
company representative in the clinic, but the patient was not be seen by a provider, nor one of the 
CDEs. This was an area with a need for improvement because of the lapse in time since the 
patient had been seen in the clinic and lack of re-evaluation for overall readiness for insulin 
pump management. Therefore, an additional CDE education visit took place during the waiting 
period of insulin pump approval/delivery, at least 1 month before the insulin pump start class 
with the company representative. 
The CDE visit focused on an introduction to the insulin pump ordered, assessment of 
patient/family diabetic management skills, and pump malfunction emergency action plan. The 
patient education visit took place in the clinic’s education room or available patient exam room 
and would last about 1 hour. The DNP student made a checklist of the diabetic education to be 
completed at this education session and finished at the follow up CDE visit post insulin pump 
start (Appendix C). The CDEs used demonstration insulin pumps to allow the patient and their 
family a first hands-on experience with their respective pump. The CDE screened the patient and 
family for insulin pump readiness with two short tests created by the DNP student. The first 
assessment, the Diabetes Pump Care assessment, was an eight-item test assessing the patient’s 
diabetic management skills and pump care knowledge (Appendix D). The second test, the Insulin 
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Pump Terminology test, assessed the patient’s and family’s level of knowledge about specific 
terminology related to insulin pump settings (Appendix E). The CDE also created a 
patient/family-centered pump malfunction emergency action plan with the help of the patient and 
family. This plan described what to do with a possible pump malfunction or unexpected pump 
disconnection. Once the plan was completed, the patient/caregiver was given a copy for their 
home and another for the school nurse. The CDE also contacted the respective school nurse to 
notify them about new insulin pump therapy.  
The CDE would discuss with the family the importance of notifying both the clinic and 
the insulin pump company representative when their pump is delivered to their home so that the 
insulin pump-start class can take place. Once the education session is over, the CDE was 
responsible for documenting what was discussed in the EHR, collect the tests and checklist, and 
store them in the assigned project folder. At that time, the CDE was also responsible for 
communicating to the provider that the patient attended the education visit so that the provider 
could write a prescription for insulin delivery orders with the pump. This allowed the patient to 
initiate pump therapy when they came in for their pump start-up class with the company 
representative. If a patient did not show for the pre-pump start education session, the front desk 
staff was responsible to contact them via telephone to reschedule the session.  
Pump Initiation 
Once the insulin pump was delivered to the patient, the patient and family attended the 
insulin pump-start class with the pump company representative in the clinic. Before leaving the 
clinic, the patient made an appointment for a follow-up education session with the CDE within a 
week of pump initiation. During this 1 week follow up, the CDE re-tested the patient and family 
about the Diabetes Pump Care assessment and the Pump Terminology test. At this time, if the 
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patient was not able to attend the first education session, completion of the educational checklist 
took place. In addition, the CDE was responsible for asking the patients if they had enough 
prescription medication refills with their fast-acting insulin used for the insulin pump as well as 
their basal insulin, which were needed in case of a pump malfunction. The CDE answered 
questions about issues with the management of their insulin pump for the first week and inquired 
about what the patient and family experienced. At the end of this educational visit, the CDE 
prompted the front desk staff to help schedule a routine follow-up appointment with their 
Pediatric endocrinologist within 2 to 3 months. The CDE then messaged the providers about who 
was seen to prompt the provider to follow up with the patient and family by phone 1 week after.  
Setting/Population 
 The quality improvement project was conducted at an outpatient pediatric endocrinology 
clinic. In 2019, there were around 20 to 40 pediatric patients between the ages of 1 to 18 years 
that were initiated on insulin pumps and currently close to 300 with them already in use. The 
DNP student and mentor estimated that about 10 patients would participate in the quality 
improvement project.  
Organizational Barriers 
 A barrier present in this clinic was the lack of availability for provider appointments due 
to the large population of patients seen at this clinic that are not type 1 diabetic patients. Initially, 
the new streamlined process required the patient to have their 1-week follow-up with their 
provider or at least 1 month post insulin pump start. However, in the organizational assessment, 
the average rate of the next available appointment was 42 days, which is higher than the 
benchmark goal of 14 days. The providers also voiced concerns that patients’ third-party 
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insurance would not cover the additional follow up visit. So, it was decided a follow up phone 
call would be included instead of an office visit.  
 An additional barrier was that the clinic had a change to a different EHR system during 
the implementation process. Initially, none of the clinic staff had been trained on the new system 
and training occurred at different intervals for each staff member. The change in EHRs caused 
obstacles during data collection and effective communication regarding the patients’ status in the 
new initiation process due to different charting processes and a new secure messaging system.  
 Barriers related to patients and families included lack of follow up communication 
notifying the clinic about their pump selection or when the pump arrives to their home. Also, 
lack of insurance approval of pump which required the provider to appeal the insulin pump order 
and show more detailed soap notes and clinical data such as blood sugar logs to validate the 
medical necessity of the device. These barriers also prolonged the wait time between pump 
decision to pump initiation. Lastly, differences patient/family primary language can cause issues 
since the insulin pump features are typically in English, not Spanish. Cultural barriers such as the 
roles of caregivers can also affect who receives proper training with the patient. For example, for 
toddlers and school age children, it is important for both parents or additional caretakers such as 
a grandparent or nanny, to receive education since children in this age group tend to be taken 
care of by additional adults outside of school hours, especially if the child is from a single parent 
home or if both parents work full time.  
Organizational Facilitators 
 A driving facilitator of this quality improvement project is that the providers, the CDEs, 
and the clinic staff shared a common responsibility for improving patient outcomes with insulin 
pumps, ensuring patient safety with the use of insulin pumps, and improving communication 
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with each other. Another facilitator is that since the clinic sees a large population of Spanish 
speaking patients and low socioeconomic backgrounds, the staff also recognized the need for this 
change process to provide high-quality care for this population who they felt needed more help 
in understanding and managing an insulin pump device. Also, the clinic has a reported 87% 
patient satisfaction experience score for the past 2 months, which is close to, but still less than 
their goal of 90%. Additionally, the clinic’s no-show rate is at 14%, which is less than the health 
system cut off a benchmark of 20%. This gives a hopeful perspective that the patients and 
families will be willing to attend the additional education visit and not miss it.  
Ethical Considerations 
 The QI project exhibited limited physical risks and harm to the participants of the 
interventions. No compensation was given to patients or families for participating. The QI 
project offered a 6th grade reading level and language education materials to patients in both 
English and Spanish. Additionally, translation services support was provided with the use of staff 
certified translator or a tablet with video translation services app to ensure that correct 
information was given to the participating families. Participants’ privacy and confidentially was 
maintained and protected throughout the project. Paper checklists and forms with patient data 
collection were maintained in the endocrinology clinic in an identified, confidential folder, 
secured in the Mentor’s office at the clinical site. The paper checklists, patient tests, and 
education checklist had a patient label placed on the paper, which was only used for these forms. 
Electronic data remained under the DNP student’s Microsoft desktop at the clinical site with 
assigned clinical site student login from the clinic’s health system. 
 The University of the Incarnate Word and the clinic site institutional review boards 
reviewed the QI project to ensure its compliance with local, state, and university regulations 
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before implementation. It was deemed as non-research by both institutions. The DNP student 
also obtained approval and support from the clinical manager, interim pediatric endocrinology 
department director, and mentor to implement the project and a letter of support was provided 
(Appendix F). 
Evaluation Plan 
In order to evaluate the effectiveness of the new streamlined process and improvement in 
patient outcomes, specific variables and data were measured and collected for each of the four 
project objectives. First, before the implementation of the new insulin pump initiation process, 
the clinic’s staff and providers were educated on new steps and project objectives. A sign-in 
sheet captured the number of staff members who attended the educational training meeting or 
who obtained individual learning from the DNP student. The goal was for 100% of staff to 
receive education by February 1st of 2020, and data of attendance were completed by that time as 
well.  
Second, patient attendance to both CDE education appointments were observed. The goal 
was for 75% of participating patients to attend both CDE education appointments. The variables 
measured for this objective were the number of scheduled CDE pump education visits per week, 
the type of CDE visit (pre-pump or follow-up post-pump), and the no show rate for both pre-
pump visit and follow-up post-pump CDE visit. This data were collected on a weekly basis by 
the DNP student. The DNP student collected the type of CDE visit through chart review of CDE 
notes. The reports on no show rates and the number of scheduled visits were collected by the 
front desk secretary.  
Third, the level of patient and family knowledge improvement was measured with the test 
scores from the Diabetes Care Assessment and Pump Terminology Test and the completed 
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education checklist of the CDE education appointment. The goal was for the patient and family 
to make an 80% passing score on both tests and to have at least 90% of the education checklist 
done by the second education session. The CDE collected these scores and checklist after each 
visit. The DNP student reviewed the education checklist for completeness weekly, and the test 
scores were reviewed weekly.  
 Fourth, the goal of decreasing 30% of adverse effects related to insulin pump misuse or 
issues was measured by the number of unexpected phone calls/clinic visits and the number of 
monthly patient hospitalizations or ER visits with insulin pump issues of patients initiated on 
insulin pumps at the start of the project. These reports were collected by front desk staff on a 
weekly and monthly basis. Furthermore, additional patient variables regarding adverse effects 
collected were the level of HbA1c at the initial visit and routine provider visits, blood glucose 
levels, the patient’s weight, growth curves, and signs and symptoms of uncontrolled diabetes 
such as polydipsia, polyphagia, polyuria, and hypoglycemic events. These were collected 
through chart review by the DNP student.  
Results 
Demographic Data 
A total of eight type 1 pediatric diabetic patients were initiated on insulin pump therapy 
during the implementation period, but a total of n =5 patients were able to complete the new 
standardized process between February 2020 through June 2020. The mean age for the new 
insulin pump patients was 10.2 years old with a mean baseline hemoglobin A1C of 9.4%. Of the 
five patients who participated in the intervention, three were male and two were female, three 
were White, two were Black non-Hispanic. Main caregivers that participated in the new process 
with patients were two parents, two grandparents, and a guardian. Additionally, 80% of the 
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patients who participated in the new process had Medicaid insurance and 60% of the 
participating families were English speaking. See table 2 for demographic data of participants.  
Table 2 
 
















The first anticipated outcome was met by 100%. Successful training was achieved by all 
clinic providers and staff about the new process through an education session before project 
implementation. Though not every provider attended, education was provided on a one to one 
basis by the DNP student to those who were not present during the education session so that 
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prior to implementation of the new process all providers were trained appropriately and 
understood their role in the project.  
Outcome 2 
 Initially, 100% of the new insulin pump patients were scheduled for the new pre pump-start 
education visit. However, only 62.5% of patients attended this visit and 37.5% did not attend, nor 
reschedule their visit. On the other hand, the post pump-start visit had 100% attendance. The 
combined attendance rate for both education visits was 62.5% attendance and 37.5% did not 
attend. The anticipated outcome was not met at 75%; however, five out of the eight patients 
received appropriate standard of care insulin pump management education.      
Outcome 3 
 Five out of the eight patients/families were able to take the diabetes care assessment and 
completed 100% of the CDE education checklist. All eight patients, however, completed 100% 
of the CDE worksheet. Pre pump-education diabetes care assessment scores had a mean average 
score of 38.7% and post-test scores showed a mean average of 85%. The outcome was partially 
met. Additionally, 80% of the five patients who took the pre-pump class were able to achieve a 
score of 80% and above (see Figure 1).  
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Figure 1 
Diabetes Pump Care Assessment Scores 
 
Outcome 4 
At baseline from the last quarter of 2019, out of the nine patients that had begun using 
insulin pumps, there were six different adverse events and one hospitalization related to pump 
malfunction. The baseline rate of adverse events related to insulin pump use was 66%. After 
implementation, only four adverse events from a total of eight new insulin pump users occurred, 
50% adverse event rate: three hyperglycemia episodes and one pump malfunction. The 
anticipated outcome to decrease the adverse event rate by 30% was not met. However, a 16% 
decrease from 66% was seen (see Figure 2). Moreover, with the implementation of the new 
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Figure 2 
Adverse Events Related to New Insulin Pump Use 
 
Discussion 
 While not all objectives were met, an essential outcome of this quality improvement 
project was the implementation of a new standardized workflow process of insulin pump 
initiation and pre-pump patient education at the facility. This allowed the use of a common 
language regarding insulin pump initiation, and timely completion of DME orders for insulin 
pumps by clinic staff, which decreased the waiting period for insulin pump delivery. Also, 
providers completed insulin pump setting orders before pump-start. This change process 
represents the use of an evidence-based approach of improving patient education and provider 
oversight of patients initiated on insulin pumps supported by the American Diabetes Association 
clinical guidelines for diabetic technologies (2019) and the American Association of Diabetes 
Educators practice statement (2018).  
 Due to the COVID-19 global pandemic that occurred during the implementation period, 
amendments to the project interventions were made for use through telemedicine. While 
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additional challenges arose with the use of telemedicine for the pre-pump start education session, 
it provided unique patient benefits such as decreased transportation costs, decreased missed time 
from school or work, and additional clinical support and healthcare access. These benefits are 
consistent with the literature that state a major benefit of telemedicine in chronic disease 
management is the ability to provide cost-effective healthcare access and disease prevention by 
allowing patients who live in rural areas or in low socioeconomic communities to have access to 
their healthcare specialist from their home (Dougherty et al., 2014; Smith & Satyshur, 2016). 
The situation also showcased the future sustainability of this quality improvement project due to 
the versatility of the project interventions to be used with telemedicine since CMS allows for 
reimbursement of diabetic education by providers and certified diabetes educators (Centers for 
Medicare and Medicaid Services, 2020).  
 Moreover, a fifth outcome for the project was created due to the COVID-19 pandemic. In 
order to adhere to best practice health measures during this time, it was crucial to track how 
many insulin pump users had documented routine care measures of hemoglobin A1C, lipid and 
thyroid panels, an annual influenza vaccine, and a blood sugar log. By ADA guidelines, 
hemoglobin A1C, must be checked every 3 months to monitor disease management (ADA, 
2019). Through a chart review of 54 insulin pump users, we found 62.5% had a documented 
hbA1C, 50% had documented lipid and thyroid labs, 42.2% had a documented annual influenza 
vaccine, and 36.3% had documented blood sugar logs. Capturing this data allowed the clinic to 
identify insulin pump users who would otherwise be missed for preventive measures during a 
pandemic where a majority of the patients are not being seen in clinic, nor going to get routine 
labs. 
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Relation to Other Evidence 
Similar to larger studies regarding insulin pump use in type I diabetes pediatric patients 
this QI project had a small sample size. Despite evidence of inequity of insulin pump use by 
minority patients in the literature, this project showed that 90% of the new insulin pump users 
had Medicaid as their insurance plan, 40% were African American, and 40% of the 
patients/families spoke Spanish as their primary language. Moreover, while the intervention only 
provided an additional 1-hour education session, the five patients/families that participated in the 
extra class had less adverse events than those who did not participate. Two of the hyperglycemia 
events were experienced by two patients that did not attend the pre-pump start class. Evidence 
from the INPUT RCT supports that increased education prior to pump start can lead to improved 
patient outcomes (Ehrmann et al., 2018). Another finding was that there were no hypoglycemic 
events following pump initiation with the new process. A decrease in hypoglycemic events has 
been noted with CSII therapy compared to multiple daily injections (Ly et al., 2013; Yeh et al., 
2012).  
Limitations           
 A significant limitation during the implementation period of this quality improvement 
project was the COVID-19 pandemic, which forced the project interventions to be carried out by 
a different approach. In order to enforce public health department and government mandates of 
social distancing to decrease virus transmission, 90% of clinic appointments were done through 
telehealth, which prompted all CDE education visits as a non-priority appointment. Initially, our 
first education sessions were canceled, and the providers of the clinic decided to defer the insulin 
pump starts during the first month of the stay-home mandate. In addition, the clinical staff, 
especially the CDEs, had limited training with telemedicine resources and limited knowledge of 
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telemedicine billing for diabetic education visits. The clinic also had to accommodate to address 
issues with HIPAA regulated telehealth apps. However, as patients received their pumps at home 
and pump orders were prescribed, an opportunity arose for the project to continue with the help 
of the provider team. As a result, the pre-pump education was carried out by two providers (the 
DNP student’s mentor and the NP), and the DNP student through phone and video conference 
with the patients/families. The DNP student also amended the interventions to be more 
online/phone call friendly. Both assessments were combined into a PowerPoint presentation that 
was emailed to the patient’s parent the day before the education and only the diabetes care 
assessment was used in a pre and post-test before and after the education session (Appendix D).  
 Additionally, another limitation was the lack of patient/family access to a computer or 
personal email to receive educational materials. For one of the six families, the education was 
given orally over the phone since the parents did not have access to a computer or email. Though 
it did not affect their scores on the post-education assessment, they were restricted on the 
telehealth experience of video interaction and lack of availability of materials at hand to look 
over, which can impact the patient and family’s understanding of insulin pump management. 
O’Connor et al. (2018) stated that minority, low-income households who primarily have public 
health insurance are noted to have less exposure to technology resulting in decreased comfort in 
using it properly. This is a crucial barrier to long term provider oversight, and patient ownership 
of insulin pump therapy since an advanced setting of insulin pumps is that patient data of insulin 
pump administration can be uploaded to cloud software and made available to both the patient 
and clinician. These comprehensive logs include information about insulin administration, 
carbohydrate intake, and blood sugars levels providing an overview of a patient’s day-to-day 
glycemic control with the use of a pump. Therefore, this patient data are as important as a 
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patient’s hemoglobin A1C level in diabetes care management since providers use a patient’s 
comprehensive insulin pump log to assess where to make changes in insulin requirements in 
relation to the patient’s glycemic variability.  
 A third limitation was the limited implementation time frame due to the COVID-19 
pandemic for accurate capturing of improvements in long-term patient outcomes such as 
improvements of HbA1c while being on pump therapy since changes can only be seen after 3 to 
4 months. Additionally, since the insulin pump users only make up about 20% of the patient 
population of the clinical facility, another limitation was a small number of participants for this 
quality improvement project.  
Recommendations 
 A multidisciplinary team approach that includes IT and data analysts is needed to sustain 
this change process by further exploring the addition of the education checklists and 
documentation of patient assessment scores in the facility’s EHR to keep track of patient issues 
with insulin pump readiness or pump malfunction especially since the health system made a 
switch to a comprehensive EHR. Gathering and quantifying data of clinic patients who were 
admitted in the hospital for DM type 1 complications or had pump malfunction issues was 
difficult to obtain during this project. However, access to a seamless EHR system that allows real 
time provider notification of clinic patients who are admitted to the health system’s hospital or 
seen in the hospital’s emergency room for a pump malfunction and DM type 1 complications 
could improve tracking of patient outcomes and gaps in this clinical process.    
Due to the impact of the COVID-19 pandemic, back up telemedicine resources, and 
clinical staff education about state and insurance plan policies regarding telemedicine are vital.  
Literature has shown that telemedicine as an adjunct tool to standard outpatient diabetes 
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management can lead to optimal patient outcomes (Dougherty et al., 2014). It is a cost-effective 
option to continued clinician oversight when patients are presented with barriers to care such as 
lack of transportation, lack of in-clinic visit availability/ time constraints, and in this case, a 
global pandemic. For this reason, additional ways to distribute the educational materials to 
patients, especially for those without access to a computer, must be addressed. An innovative 
way to address this issue would be by creating a pump therapy educational video or sound 
recording that is uploaded to clinic’s website or assigned to the patient’s clinic portal account so 
that it can be easily accessed through a cell phone, tablet or computer. This is a feasible idea 
since a majority of parents and children currently have access to mobile devices or tablets that 
have access to the internet.  
 Additionally, observations made by the two providers who participated in the project 
implementation were the success of improved patient/family engagement and communication. 
Both the providers agreed that educating the patients themselves and having that one-on-one 
time through a video and/or phone call outside of the clinic setting allowed patients and parents 
to be more comfortable in asking questions and voicing concerns they had in their diabetes 
management. This is an area to explore for its effects on patient satisfaction. Perhaps, after 
initiation of insulin pump therapy patients and families can request a telemedicine visit, whether 
it be with a CDE or provider, to reinforce evaluation of proper insulin pump use or obstacles in 
care instead of having to wait for an available in clinic appointment. This is an innovative 
possibility of extending the patient-provider-healthcare team relationship. 
Implications for Practice 
 Informed problem-solving skills in response to insulin pump failure was the focus of the 
education provided in both education sessions. Evidence shows that adverse events from insulin 
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pump misuse, such as DKA, arise from lack of anticipatory guidance of pump-troubleshooting 
strategies (Evert et al., 2016; Grunberger et al., 2014; Wheeler et al., 2014). Evert et al. (2014), 
recommended the use of a short waiting room questionnaire to be given to address insulin 
infusion set issues during the clinic visit. Therefore, it calls attention to continue to carry out 
quality improvement of continuous assessment of these patient skills at every future routine visit 
to cue providers of education gaps.  
Advanced practice registered nurses are experts of patient and family-centered care. 
Therefore, they play a vital role in leading quality improvement by not only using evidence-
based strategies that encourage patient ownership of insulin pump therapy, but also support 
interprofessional collaboration and effective use of innovative technology and communication 
methods to improve patient outcomes. The new protocol is a sustainable systematic change since 
each staff member had their own responsibilities and the DNP prepared nurse was able to 
initiate, guide, and support the implementation of evidenced-based standards of care. Through a 
multidisciplinary approach and provider leadership, the project was able to be amended to use 
telehealth. An additional sustainable outcome was that after discussion of the project results with 
the provider team, the chief department head requested that the patient educational materials be 
incorporated into the medical residents’ educational curriculum in order improve future pediatric 
provider competence of insulin pump management. Ultimately, it is the provider’s responsibility 
to assess patient/family readiness for change in therapy as well as to monitor patient outcomes. A 
DNP prepared nurse recognizes this responsibility by tailoring the change process to decrease 
health disparities and barriers to care. 
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Appendix A 










Time Frame Personnel 
 
Arrange an education 
session/meeting to 
introduce QI measure 
to staff 
N/A—inform 










meeting; 1 min 
 
Send email by 
January 24th.  
DNP Student 
Create teaching 
handout for education 
session of staff. 
Computer and 
printing paper 






































• Insulin Pump 
terminology 
Test  
• CDE education 
checklist 
  
Obtain approval of 











































NP, CDEs, MAs, 
clinic manager, 
and front desk 
receptionists 
Obtain buy-in and 











project; 20 mins 
DNP student and 
staff 
Place copy of 
streamlined  QI project 
at MA/Nurse station in 
protocols folder 














project; 1 min  
DNP student 
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Place confidential 
folder for completed 
education packet that 
includes tests and CDE 
















project; 1 min  
DNP student 
Initial Provider Visit 




















Call back to patient 
room and obtain 
patient’s vital signs 























the start of the 
patient care 




and blood sugar log 
from glucometer if 
with patient 













Physician enters room; 
assesses patient and 
evaluates eligibility for 
insulin pump therapy 
Stethoscope, 



















meets eligibility for 
insulin pump therapy  










CDE enters room; 
provides patient and 
family brochures about 
different insulin pumps 
and “Pathway to 
Insulin Pump Therapy” 
handout 






















Patient check-out n/a Hallway
or Front 
Desk 
















N/A Patient will be 






















































Provider of session and 





Office n/a 1-3 min CDE & provider 
Pump-Start Education 
Session 
Schedule post pump 
CDE education visit at 












place 1-2 times 





























post pump start.  





CDE charts in SOAP 
note about completed 
EMR SOAP 
note 
Office n/a 5 min CDE 
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education session and 




message and calls 
patient and family by 
phone 
Office Phone Office n/a 3-5min  
Should take 
place within a 






100 % of staff will 
attend education 
session  




session and on 
one-one basis 
within first 
week of project 
implementation 
DNP student 
75% of participating 
patients to attend both 
CDE education 
appointments 
o The number of 
scheduled CDE 
pump education 
visits per week 
o The type of CDE 
visit ( pre-pump or 
follow-up post-
pump), 
o The no show rate 
for both pre-pump 









DNP student and 
Front desk 
secretary  




The patient and family 
to make an 80% 
passing score on both 
tests and to have at 
least 80% of the 













N/A  The CDE will 
be collecting 
these scores and 
checklist at 
every visit (1-
2x a week). 
The DNP 







CDE and DNP 
student.  
Decreasing 30% of 
adverse effects related 
to insulin pump misuse 
or issues is measured 
by the number of 
unexpected phone 
calls/clinic visits and 
the number of monthly 
patient hospitalizations 
or ER visits with 






phone calls or 
visits to the 
clinic will be 
collected 








• Front desk 
• DNP Student 
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Additional staff 














Results of the 





























the staff’s lunch 
hour 














DNP student; all 
staff members 
including MD, 
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CDE Education Checklist for Pump Therapy 
 
 
TOPIC DATE INITIALS 
Understating Pump Therapy 
 Insulin Type 
 Basal Rate 
 Meal Bolus 
 Insulin Sensitivity/ Correction Factor 
 Infusion Set 
 When to change Set 
 Pump Terminology Quiz: _______ score 
  
Skin Safety 
 Checking pump placement 
 Lipohypertrophy 
 Rotating sites 
  
Blood Glucose Testing 




 Carb counting 
 Using Food Labels 
 Insulin to carb ratio 
 Correction scale 
 Proper Snacks 
 Diabetes Care Assessment: ______ score 
  
Exercise 
 Pump Safety 
 BG checks 
 Hypoglycemia 
 Proper snacks 
  
Hypoglycemia/ Hyperglycemia/ DKA 
 Diabetes Action Plan 
 Signs and Symptoms 
 Ketone testing 
 Glucagon 
 Sick Days 
  
Pump Therapy 
 When to call the doctor/clinic 
 What do if pump fails or is discontinued 
 How to order pump supplies 
 Pump back up Plan 
 Pump Orders: date__________________ 
 
  




Diabetes Pump Care Assessment in English and Spanish 
Diabetes Pump Care Assessment 
Circle the correct answers.  
1. Which type of insulin is used in insulin pump therapy? 
A. Fast acting 
B. Long Acting 




D. Novolog  
   
3. When using a pump, which type of insulin delivery should keep blood sugar stable 
when you are not eating?  
A. Basal  
B. Bolus 
C. Temporary Basal          
       
4. When using a pump, which type of insulin delivery is used to cover food eaten or to 
lower a high blood sugar?          




5. If your child has an unexpected high blood sugar and you give them a correction 
dose of insulin with their pump, when should you recheck their blood sugar to make 
sure the pump is working properly?  
A. Every 15 minutes for 1 hour 
B. 30 minutes after       
C. 1 hour after 
6.  If your child’s blood sugar does not go down after a correction dose given with the 
pump, what is the first thing should you do?  
A. Call your provider      
B. Trouble shoot your pump 
C. Call 911 or go to ER 
 
7. What is the longest amount of time your child can be disconnected from their pump 
before you need to check their blood sugar? 
INSULIN PUMPS & PEDIACTRIC TYPE 1 DIABETES 65 
 
 
A. 30 min 
B. 1 hour       
C. 3 hours  
D. 4-5 hours 
 
8. If your pump fails, you are told to follow the sliding scale shown here.  
 
Insulin you take 
based upon your 
blood sugar 
levels.  




0-150 0  
151-200 1  
201-250 2  
251-300 3  
301-350 4  
351-400 5 
8a. How many units would you take for a blood sugar of 295? _____units 
8b. What type of insulin would you use if your pump stops working?  
A. Humalog and Lantus   
B. Tresiba only 
C. Novolog only 
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Revisión del Cuidado de Diabetes  
con el Uso de Una Bomba de Insulina 
Encierre en un círculo la respuesta correcta 
1. ¿Qué tipo de insulina se usa en la terapia con bomba de insulina?  
 a. De acción rápida                      
 b. De acción larga 
2. ¿Qué es una insulina de acción rápida? Circule las respuestas correctas. 
 a. Lantus                    
 b. Novolog                    
 c. Tresiba                     
 d. Humalog 
3. Al usar una bomba, ¿qué tipo de suministro de insulina debería mantener estable el 
azúcar en la sangre cuando no está comiendo? 
a. Basal                      
 b. Bolus                         
 c. Basal Temporal 
4. Cuando se usa una bomba, ¿qué tipo de suministro de insulina se usa para cubrir los 
alimentos ingeridos o para reducir el nivel alto de glucosa en la sangre?  
 a.  Basal Temporal                 
 b. Basal                      
 c. Bolus 
5. Si su hijo tiene un nivel alto de azúcar en la sangre y usted le da una dosis correctiva 
de insulina con su bomba, ¿cuándo debe volver a verificar su nivel de azúcar en la 
sangre para verificar que su bomba de insulina esté funcionando correctamente? 
a. Cada 15 minutos durante 1 hora           
 b. 30 minutos después         
 c. 1 hora después 
6. Si el nivel de azúcar en la sangre de su hijo no baja después de una dosis de 
corrección administrada con la bomba, ¿qué debe hacer? 
a. Llamar a su doctor         
 b. Chequear que su bomba esté funcionando como las indicaciones  
 c. Llamar al 911 o ir a la sala de emergencias 
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7. ¿Cuál es la mayor cantidad de tiempo que su hijo puede desconectarse de la bomba 
antes de que necesite controlar su nivel de azúcar en la sangre?   
 a. 30 minutos         
 b. 1 hora           
 c. 3 horas            
 c. 4-5 horas 
8. Si su bomba falla, se le indica que siga la escala deslizante que se muestra aquí. 
Si el nivel de 
azucar esta en 




0-150 0  
151-200 1  
201-250 2  
251-300 3  
301-350 4  
351-400 5 
 
a. ¿Cuántas unidades tomarías para un azúcar en la sangre de 295? ___ unidades 
b. ¿Qué tipo de insulina usarías si tu bomba deja de funcionar? 
a. Humalog y Lantus         
 b. Solo Tresiba         
 c. Solo Humalog           
 d. Tresiba y Lantus 
  




Insulin Pump Vocabulary Review and Quiz in English and Spanish 




Rapid- Acting Insulin Insulin that is used by the insulin pump.  
Will begin to work about 15 minutes after 
injection, peaks in about 1 hour, and 
continues to work for 2 to 4 hours.  
Basal rate The continuous dose of insulin that is 
delivered by the insulin pump 24 hours a 
day, measured by insulin units per hour 
Bolus  Extra insulin needed before meals and other 
times when your child’s blood sugar is high 
Temp basal rate A basal rate that that you can set to the 
amount of insulin temporarily delivered over 
a given amount of time.  
Insulin sensitivity factor (ISF) or 
Correction Factor 
The value that indicates how much one unit 
of insulin will lower your child’s blood sugar 
 
Active Insulin or Insulin on Board (IOB) The length of time that insulin remains active 
and available in your child’s body after a 
bolus 
Insulin to Carb Ratio Amount of carbs (in grams) covered by one 
unit of insulin  
Target Blood glucose The ideal range at which you would like your 
blood sugar to be 
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Insulin Pump Vocabulary Quiz 
Match the term to the correct definition. 
 
 
A. Basal Rate 
B. Bolus 
C. Temp Basal Rate 
D. Insulin Sensitivity Factor/ Correction Factor 
E. Insulin on Board 
F. Insulin to Carb ratio 
G. Target blood glucose 
 
 
1. ______  The ideal range at which you would like your blood sugar to be. 
2. ______ Amount of carbs (in grams) covered by one unit of insulin. 
3. ______ The continuous dose of insulin that is delivered by the insulin pump 
measured by insulin units per hour. 
4. ______ The length of time that insulin remains active and available in your child’s 
body after a bolus. 
5. ______ A basal rate that that you can set to the amount of insulin temporarily 
delivered over a given amount of time. 
6. ______ The value that indicates how much one unit of insulin will lower your child’s 
blood sugar. 
7. ______ Extra insulin needed before meals and other times when your child’s blood 
sugar is high. 
 
8. ______ Insulin that is used by the insulin pump. Will begin to work about 15 minutes 
after injection, peaks in about 1 hour, and continues to work for 2 to 4 hours.  
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Insulina de Accion Rápida La insulina que usa la bomba de insulina. 
Comenzará a funcionar aproximadamente 
15 minutos después de la inyección, 
alcanzará su punto máximo en 
aproximadamente 1 hora y continuará 
funcionando durante 2 a 4 horas. 
Basal rate 
velocidad basal 
La dosis continua de insulina suministrada 
por la bomba de insulina que estará medida 
por unidades de insulina por hora 
Bolus  
dosis de insulina rápida 
La insulina adicional necesitada antes de las 
comidas y otras veces cuando el nivel de 
azúcar en la sangre de su hijo esta alto 
Temp basal rate 
velocidad basal temporaria 
Una dosis basal que usted puede programar 
para suministrar temporalmente sobre un 
tiempo elegido.  
Insulin sensitivity factor (ISF) o 
Correction Factor 
Factor de sensibilidad de la insulina o Factor 
de corrección 
 
El valor que indica cuánto una unidad de 
insulina puede reducir el nivel de azúcar de 
la sangre de su hijo 
 
Active Insulin or Insulin on Board (IOB) 
Insulina activa o insulina abordo 
El tiempo que la insulina permanece activa y 
disponible en el cuerpo de su hijo después 
de un bolus 
Insulin to Carb Ratio 
Proporción de insulina a carbohidratos 
Cantidad de carbohidratos (en gramos) 
cubiertos por una unidad de insulina 
Target Blood glucose 
Objetivo del nivel de glucosa en la sangre 
El rango ideal en el que le gustaría tener su 
nivel de azúcar en sangre 
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Cuestionario de vocabulario de la bomba de insulina 
Elija el termino con la definición correcta.  
 
 
H. Insulina de Accion Rapida 
I. Basal Rate 
J. Bolus 
K. Temp Basal Rate 
L. Insulin Sensitivity Factor 
M. Insulin on Board 
N. Insulin to Carb ratio 
O. Target blood glucose 
 
1. ______ El rango ideal en el que le gustaría tener su nivel de azúcar en sangre. 
2. ______ Cantidad de carbohidratos (en gramos) cubiertos por una unidad de 
insulina. 
3. ______ La dosis continua de insulina suministrada por la bomba de insulina que 
estará medida por unidades de insulina por hora. 
4. ______ El tiempo que la insulina permanece activa y disponible en el cuerpo de 
su hijo después de un bolus. 
5. ______ Una dosis basal que usted puede programar para suministrar 
temporalmente sobre un tiempo elegido. 
6. ______ El valor que indica cuánto una unidad de insulina puede reducir el nivel 
de azúcar de la sangre de su hijo. 
7. ______ La insulina adicional antes de las comidas y otras veces cuando el nivel 
de azúcar en sangre de su hijo esta alto. 
8. ______ La insulina que usa la bomba de insulina. Comenzará a funcionar 
aproximadamente 15 minutos después de la inyección, alcanzará su punto 
máximo en aproximadamente 1 hora y continuará funcionando durante 2 a 4 
horas. 
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